Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model.

Reichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, Halle A, Petzold GC. · 2019

Read Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model. by Reichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, Halle A, Petzold GC. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6365929.txt.

Introduction

Reichenbach and co-authors present a research article in EMBO Molecular Medicine on astrocyte reactions in Alzheimer's disease. Astrocytes near amyloid plaques become reactive, a change driven by the transcription factor Stat3. The team deleted Stat3 only in astrocytes of APP/PS1 mice, a standard Alzheimer's model.

Mice without astrocyte Stat3 had lower amyloid levels and fewer plaques. Nearby microglia cleared more amyloid, and inflammatory signals dropped. Brain network imbalance and memory decline were largely prevented. A Stat3-blocking drug given to the whole body produced the same protection. The authors present Stat3-driven astrogliosis as a promising treatment target.

Catalog record

CREATORReichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, Halle A, Petzold GC.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE71 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6365929

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Inhibition of Stat3‐mediated astrogliosis ameliorates pathology in an Alzheimer's disease model By Nicole Reichenbach, Andrea Delekate, Monika Plescher, Franziska Schmitt, Sybille Krauss, Nelli Blank, Annett Halle, Gabor C Petzold Published in: EMBO Molecular Medicine DOI: 10.15252/emmm.201809665 ABSTRACT Abstract Reactive astrogliosis is a hallmark of Alzheimer's disease (AD), but its role for disease initiation and progression has remained incompletely understood. We here show that the transcription factor Stat3 (signal transducer and activator of transcription 3), a canonical inducer of astrogliosis, is activated in an AD mouse model and human AD. Therefore, using a conditional knockout approach, we deleted Stat3 specifically in astrocytes in the APP/PS1 model of AD. We found that Stat3‐deficient APP/PS1 mice show decreased β‐amyloid levels and plaque burden. Plaque‐close microglia displayed a more complex morphology, internalized more β‐amyloid, and upregulated amyloid clearance pathways in Stat3‐deficient mice. Moreover, astrocyte‐specific Stat3‐deficient APP/PS1 mice showed decreased pro‐inflammatory cytokine activation and lower dystrophic neurite burden, and were largely protected from cerebral network imbalance. Finally, Stat3 deletion in astrocytes also strongly ameliorated spatial learning and memory decline in APP/PS1 mice. Importantly, these protective effects on network dysfunction and cognition were recapitulated in APP/PS1 mice systemically treated with a preclinical Stat3 inhibitor drug. In summary, our data implicate Stat3‐mediated astrogliosis as an important therapeutic target in AD. INTRODUCTION Alzheimer's disease (AD) is a common and chronic neurodegenerative disorder characterized by cognitive decline. An early and characteristic hallmark of the disease in patients and mouse models is that astrocytes around β‐amyloid (Aβ) plaques undergo prominent morphological changes, known as reactive astrogliosis (Carter et al, 2012; Pekny et al, 2015). While reactive astrogliosis is a ubiquitous and sustained response mechanism of the brain to acute or chronic injury (Burda & Sofroniew, 2014; Pekny & Pekna, 2014), its underlying mechanisms and the consequences for AD pathogenesis and other conditions have remained incompletely understood. However, given that the primary and most important role of astrocytes in the brain is to maintain neuronal health (Barres, 2008), it seems intuitive that astrogliosis may be an important target to alleviate neurodegeneration in brain diseases. Previous studies have shown that pharmacological or transgenic interference with astroglial signaling pathways that are pathologically activated in models of chronic neurodegenerative diseases including AD can restore network function and support neuronal survival (Delekate et al, 2014; Tong et al, 2014; Reichenbach et al, 2018). However, a preclinical exploration of reactive astrogliosis as a potential therapeutic target in AD has been lacking. One of the key regulators of many pathways associated with astrogliosis is signal transducer and activator of transcription 3 (Stat3), a transcription factor that is activated through phosphorylation by Janus kinases (JAK) in response to cytokines, intercellular mediators, and growth factors (Villarino et al, 2017). JAK/Stat3 activation in astrocytes has been detected in a plethora of conditions and disease models that are associated with astrogliosis, including stroke (Justicia et al, 2000), AD (Ben Haim et al, 2015), spinal cord injury (Okada et al, 2006; Herrmann et al, 2008), multiple sclerosis (Qin et al, 2012), and epilepsy (Xu et al, 2011). Interestingly, but perhaps not surprisingly given that different context‐dependent variations of astrogliosis exist (Liddelow et al, 2017), the consequences of Stat3 activation in astrocytes appear to depend on the severity of astrogliosis as well as the underlying disease. For example, inhibiting Stat3 activation in astrocytes in spinal cord injury, where strong astrogliosis contributes to scar formation, worsens outcome (Okada et al, 2006; Herrmann et al, 2008), but has the opposite effect in models of multiple sclerosis (Qin et al, 2012) or neonatal hypoxic brain damage (Hristova et al, 2016). Hence, Stat3 may aggravate or alleviate neurodegeneration in a context‐dependent manner (Tyzack et al, 2017), indicating that the full repertoire of cellular pathways initiated by Stat3 signaling remains to be investigated. We aimed to preclinically test the applicability of Stat3‐mediated astrogliosis as a potential target for future therapies. Therefore, we sought to determine the molecular pathways and consequences of an astrocyte‐specific conditional deletion of Stat3 on pathological hallmarks, network function, neuroinflammation, and cognitive dysfunction in an AD mouse model. RESULTS Effective astrocyte‐specific deletion of Stat3, a regulator of astrogliosis in AD To delete Stat3 in astrocytes, we used mice expressing tamoxifen‐inducible Cre recombinase (CreERT) under the astrocyte‐specific connexin‐43 (Cx43) promoter (Eckardt et al, 2004). To confirm efficacy and astrocyte selectivity, we first crossed these mice to the Ai9 (tdTomato‐loxP) reporter line that expresses tdTomato following Cre recombination. Injection of tamoxifen into 6‐week‐old Cx43‐Cre::tdTomato‐loxP mice resulted in strong tdTomato expression. Immunohistochemistry at 8 or 11 months revealed a high selectivity for astrocytes. ~90 % of tdTomato‐positive cells were astrocytes (Fig 1A and B), and the small fractions of remaining cells were either neurons (~5–6%), NG2 cells (~4%), or oligodendrocytes (< 1%) (Fig 1A and B). [Figure: Stat3 activation in an AD model is efficiently reduced using a conditional knockout strategy A, BTo verify the specificity of Cx43‐CreERT mice for astrocytes, mice were crossed to a tdTomato reporter line to induce Cre‐dependent tdTomato expression after tamoxifen administration. TdTomato fluorescence was enhanced with an antibody against red fluorescent protein, and astrocytes were stained with antibodies against GFAP or S100β (not shown). Merged images and quantification show efficient and widespread tdTomato expression specific for astrocytes (arrowheads indicate tdTomato and GFAP overlap) in 8‐ and 11‐month‐old animals. Expression was low in neurons (stained with NeuN, not shown) and negligible in NG2 cells and oligodendrocytes. Scale bars, 250 μm (upper panel) and 50 μm (lower panel).CThe majority of peri‐plaque astrocytes in APP/PS1‐Stat3WT were positive for activated/phosphorylated Stat3 (pStat3) in the cortex (Cx) and hippocampus (HC), whereas the fraction of pStat3‐positive astrocytes was significantly lower in APP/PS1‐Stat3KO mice in both regions (n = 8 mice (three females and five males) per group; age, 8 months; *P < 0.05, Mann–Whitney test). The occurrence of pStat3 in WT‐Stat3KO and WT‐Stat3WT mice was negligible (n = 8 mice (four females and four males) per group; age, 8 months; Mann–Whitney test).D, EExamples of Stat3 activation in APP/PS1‐Stat3KO and APP/PS1‐Stat3WT. (D) pStat3 (arrowheads) was abundantly present in reactive astrocytes (identified by GFAP) around plaques (identified by IC16). (E) Only few astrocytes were positive for pStat3 in APP/PS1‐Stat3WT mice. Scale bars, 50 μm.F, GIn postmortem brain sections from AD patients, we detected nuclear pStat3 (arrows) in the majority of peri‐plaque reactive astrocytes (identified by GFAP) in the cortex and hippocampus (plaques were stained with methoxy‐XO4, arrowheads). Scale bar, 50 μm. In total, n = 4 cortical and n = 3 hippocampal sections were analyzed.Data information: Data are represented as mean ± SEM.] Next, we investigated the role of Stat3 in the APPswe/PS1∆E9 (APP/PS1) mouse model of AD (Jankowsky et al, 2004), using a mouse line in which exons 12–14 of the Stat3 gene are flanked by loxP sites, enabling Cre‐mediated functional Stat3 deletion (Alonzi et al, 2001). We then generated APP/PS1tg/wt::Cx43‐Cretg/wt::Stat3loxP/loxP (APP/PS1‐Stat3KO) mice and activated Cre recombination by tamoxifen injection at 6 weeks. APP/PS1tg/wt::Cx43‐Crewt/wt::Stat3loxP/loxP (APP/PS1‐Stat3WT), APP/PS1wt/wt::Cx43‐Cretg/wt::Stat3loxP/loxP (WT‐Stat3KO), and APP/PS1wt/wt::Cx43‐Crewt/wt::Stat3loxP/loxP (WT‐Stat3WT) mice served as controls and were also injected with tamoxifen at the same age. We found that 46 ± 10% of all GFAP‐positive astrocytes in the cortex and 41 ± 8% in the hippocampus were positive for pStat3. These ratios were even higher in the peri‐plaque regions, where the

Read the complete text